RNTX · Rein Therapeutics Inc.

Rein Therapeutics represents a high-risk, high-reward clinical-stage biotech play in the orphan pulmonary fibrosis space, where LTI-03 targets idiopathic pulmonary fibrosis (IPF)—a devastating disease lacking curative therapies. The RENEW Phase 2 trial, with first patient dosed in March 2026 and topline data slated for Q4 2026, tests inhaled LTI-03's ability to preserve lung function via biomarkers and imaging across 120 patients globally. Success here could validate the Cav1 peptide platform, but failure risks total value erosion given the company's $401M accumulated deficit and paused LTI-01 program. Financially precarious with just $3.2M cash at year-end 2025 and a working capital deficit, the $44M net proceeds (post-note repayment) extend runway to April 2027, buying time for trial readouts amid ongoing burn. Dilution is severe—new investors face $1.01/share hit from $(0.11) book value, with post-money shares jumping to 58M and overhang from 12M convertible preferred, 6.6M warrants (many at $0.001), and 3M options representing ~35% potential dilution. Voss Capital's 15.9% stake signals activist interest, while insiders hold 4.4%. Underwriting by Konik with 7% discount, 120-day lock-up, and rep warrants adds standard terms but underscores microcap dynamics. Auditors flag going concern across reports, emphasizing execution risk on single-asset bet. Nasdaq RNTX listing maintains visibility, but compliance looms if trials slip. Investors betting on positive Phase 2 data get leveraged upside in underserved fibrosis market, but must stomach near-term financing needs and binary trial outcome.